Should students be allowed — or encouraged — to take “smart drugs” so they can get better grades?
That will be the question on the table on Monday when the public affairs program Intelligence Squared — IQ2 — brings its lively debate format to George Washington University.
Here’s how it works. IQ2 presents a motion for debate — in this case, “College students should be allowed to take smart drugs.” The premise is explained: “Off-label use of ‘smart drugs’ — pharmaceuticals meant to treat disorders like ADHD, narcolepsy and Alzheimer’s — are becoming increasingly popular among college students hoping to get ahead by helping them to stay focused and alert for longer periods of time. But is this cheating? Should their use as cognitive enhancers be approved by the FDA, the medical community and society at large? Do the benefits outweigh the risks?”
Arguing for the motion will be Anjan Chatterjee, the chair of neurology at Pennsylvania Hospital, and Nita Farahany, director of the Duke Initiative for Science & Society. Arguing against will be Eric Racine, director of a neuroethics research unit in Montreal, and Nicole Vincent, an associate professor of philosophy, law and neuroscience at Georgia State University.